KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Asset Writedowns and Impairment (2016 - 2025)

TherapeuticsMD's Asset Writedowns and Impairment history spans 14 years, with the latest figure at $1.3 million for Q1 2025.

  • For Q1 2025, Asset Writedowns and Impairment changed N/A year-over-year to $1.3 million; the TTM value through Mar 2025 reached $1.3 million, changed N/A, while the annual FY2024 figure was $1.3 million, N/A changed from the prior year.
  • Asset Writedowns and Impairment reached $1.3 million in Q1 2025 per TXMD's latest filing, up from $7000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $1.3 million in Q1 2025 to a low of -$7000.0 in Q4 2021.
  • Average Asset Writedowns and Impairment over 5 years is $266888.9, with a median of $215000.0 recorded in 2021.
  • The largest YoY upside for Asset Writedowns and Impairment was 462.08% in 2021 against a maximum downside of 101.4% in 2021.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at -$7000.0 in 2021, then skyrocketed by 3928.57% to $268000.0 in 2022, then tumbled by 77.99% to $59000.0 in 2023, then tumbled by 88.14% to $7000.0 in 2024, then soared by 17914.29% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Asset Writedowns and Impairment are $1.3 million (Q1 2025), $7000.0 (Q4 2024), and $59000.0 (Q1 2023).